Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer
To evaluate the progression free survival of patients with extensive stage small cell lung cancer treated with anlotinib combined with EP/CE regimen
Extensive-stage Small Cell Lung Cancer
DRUG: anlotinib
PFS, the progression free survival of patients with extensive stage small cell lung cancer treated with anlotinib combined with EP/CE regimen, from the first cycle of treatment (day one) to two month after the last cycle
To evaluate the progression free survival of patients with extensive stage small cell lung cancer treated with anlotinib combined with EP/CE regimen To evaluate the safety, tolerability, overall survival (OS), objective response rate (ORR), disease control rate (DCR), and quality of life (QoL) of patients with extensive stage small cell lung cancer treated with anlotinib